Cangrelor

WikiDoc Resources for Cangrelor
Articles
Most recent articles on Cangrelor Most cited articles on Cangrelor Review articles on Cangrelor Articles on Cangrelor in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cangrelor Images of Cangrelor Photos of Cangrelor Podcasts & MP3s on Cangrelor Videos on Cangrelor
Evidence Based Medicine
Cochrane Collaboration on Cangrelor Bandolier on Cangrelor TRIP on Cangrelor
Clinical Trials
Ongoing Trials on Cangrelor at Clinical Trials.gov Trial results on Cangrelor Clinical Trials on Cangrelor at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cangrelor NICE Guidance on Cangrelor NHS PRODIGY Guidance FDA on Cangrelor CDC on Cangrelor
Books
Books on Cangrelor
News
Cangrelor in the news Be alerted to news on Cangrelor News trends on Cangrelor
Commentary
Blogs on Cangrelor
Definitions
Definitions of Cangrelor
Patient Resources / Community
Patient resources on Cangrelor Discussion groups on Cangrelor Patient Handouts on Cangrelor Directions to Hospitals Treating Cangrelor Risk calculators and risk factors for Cangrelor
Healthcare Provider Resources
Symptoms of Cangrelor Causes & Risk Factors for Cangrelor Diagnostic studies for Cangrelor Treatment of Cangrelor
Continuing Medical Education (CME)
CME Programs on Cangrelor
International
Cangrelor en Espanol Cangrelor en Francais
Business
Cangrelor in the Marketplace Patents on Cangrelor
Experimental / Informatics
List of terms related to Cangrelor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Template:Chembox E number

Cangrelor

File:Cangrelor.png
Names
IUPAC name [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
Identifiers
CAS Number	163706-06-7 Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL1097279 N
ChemSpider	8029718 N
ECHA InfoCard
IUPHAR/BPS	1776
PubChem CID	9854012
InChI InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1 N Key: PAEBIVWUMLRPSK-IDTAVKCVSA-N N InChI=1/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1 Key: PAEBIVWUMLRPSK-IDTAVKCVBK
SMILES CSCCNC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F
Properties
Chemical formula	C17H25Cl2F3N5O12P3S2
Molar mass	776.35 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Overview

Cangrelor is a P2Y₁₂ inhibitor under investigation as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.

Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009. The BRIDGE study, for short term use prior to surgery, continues. The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction. Reviewers have questioned the methodology of the trial.

Medical use

According to recent phase 3 randomized trials, a cangrelor–clopidogrel combination is safe and has been found to be more effective than standard clopidogrel treatment at reducing ischemic events in the heart, without increasing major bleeding in the treatment of stenotic coronary arteries. The advantages of this drug combination are most prominent in patients with myocardial infarction.

Available antiplatelet drugs have delayed onset and offset of action. Since cangrelor’s effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who require P2Y12 inhibition.

Current evidence regarding cangrelor therapy is limited by the lack studies assessing cangrelor administration in conjunction with either prasugrel or ticagrelor.

Pharmacology

Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite . This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion. The pharmacokinetics of cangrelor has allow it to rapidly achieve steady-state concentrations with a clearance of 50 L/h and a half-life of 2.6 to 3.3 minutes. Cessation of its administration is associated with rapid removal, and normal platelet function is restored within 1 hour.

Adverse effects

Despite fewer bleeding events during cardiac surgery, cangrelor carries the risk of potential autoimmune reactions manifesting as dyspnea. Potential mechanisms for dyspnea following cangrelor treatment include: repeated binding and unbinding cycles, impaired platelet turnover, and lung sequestration or apoptosis of overloaded destructive platelets. The dyspnea risks following cangrelor treatment, suggest a common mechanism linking transfusion-related acute lung injury, dyspnea, and reversible platelet inhibition.

The risk of dyspnea after intravenous cangrelor is smaller when compared with other reversible platelet P2Y12 receptor inhibitors, however, it is still significantly higher when compared to irreversible oral antiplatelet drugs or intravenous glycoprotein IIb/IIIa inhibitors; which do not increase the incidence of dyspnea at all.